Compare INTZ & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | BCDA |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | 52 | 21 |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 12.9M |
| IPO Year | 2020 | N/A |
| Metric | INTZ | BCDA |
|---|---|---|
| Price | $0.73 | $0.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.75 | ★ $25.00 |
| AVG Volume (30 Days) | 136.6K | ★ 5.7M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,015,000.00 | N/A |
| Revenue This Year | $25.34 | N/A |
| Revenue Next Year | $14.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.69 | $0.84 |
| 52 Week High | $2.64 | $2.45 |
| Indicator | INTZ | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 44.29 |
| Support Level | N/A | $0.84 |
| Resistance Level | $1.20 | $1.36 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 14.81 | 7.36 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).